Abstract
Ozanimod and ponesimod are both sphingosine 1-phosphate receptor modulators approved by the FDA for treatment of relapsing forms of multiple sclerosis (MS). Without head-to-head trials between these 2 treatments, we performed a matching-adjusted indirect comparison (MAIC) of efficacy and safety outcomes between ozanimod and ponesimod for MS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
